Your browser doesn't support javascript.
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.
Focosi, Daniele; Tuccori, Marco; Baj, Andreina; Maggi, Fabrizio.
  • Focosi D; North-Western Tuscany Blood Bank, Pisa University Hospital, Via Paraisa 2, 56124 Pisa, Italy.
  • Tuccori M; Division of Pharmacovigilance, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy.
  • Baj A; Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
  • Maggi F; Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
Viruses ; 13(7)2021 06 23.
Article in English | MEDLINE | ID: covidwho-1289016
ABSTRACT
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasma / Viral Vaccines / SARS-CoV-2 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: V13071211

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasma / Viral Vaccines / SARS-CoV-2 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: V13071211